Publication: Plasmodium vivax susceptibility to ferroquine
Issued Date
2010-05-01
Resource Type
ISSN
10986596
00664804
00664804
Other identifier(s)
2-s2.0-77951228214
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antimicrobial Agents and Chemotherapy. Vol.54, No.5 (2010), 2228-2230
Suggested Citation
M. L. Leimanis, A. Jaidee, K. Sriprawat, S. Kaewpongsri, R. Suwanarusk, M. Barends, A. P. Phyo, B. Russell, L. Renia, F. Nosten Plasmodium vivax susceptibility to ferroquine. Antimicrobial Agents and Chemotherapy. Vol.54, No.5 (2010), 2228-2230. doi:10.1128/AAC.01572-09 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/29696
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Plasmodium vivax susceptibility to ferroquine
Abstract
The novel organometallic chloroquine analog ferroquine (SSR 97193) is effective against chloroquine-resistant Plasmodium falciparum. The ex vivo efficacy of ferroquine against Plasmodium vivax isolates was tested. Ferroquine has a potent ex vivo effect on P. vivax schizont maturation (median 50% inhibitory concentration, 15 nM; n = 42). No significant cross-sensitivity between ferroquine and other antimalarials was detected. This drug may be a suitable replacement for chloroquine in the treatment of drug-resistant P. vivax malaria. Copyright © 2010, American Society for Microbiology. All Rights Reserved.